Last reviewed · How we verify
Bevacizumab, Cyclophosphamide, Capecitabine
This combination uses a monoclonal antibody to block tumor blood vessel formation while chemotherapy agents directly kill cancer cells.
This combination uses a monoclonal antibody to block tumor blood vessel formation while chemotherapy agents directly kill cancer cells. Used for Metastatic breast cancer, Colorectal cancer, Non-small cell lung cancer.
At a glance
| Generic name | Bevacizumab, Cyclophosphamide, Capecitabine |
|---|---|
| Also known as | Avastin, Xeloda |
| Sponsor | Swiss Cancer Institute |
| Drug class | Combination therapy: monoclonal antibody (anti-VEGF) + chemotherapy |
| Target | VEGF (vascular endothelial growth factor) for bevacizumab; DNA for cyclophosphamide and capecitabine |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a VEGF inhibitor that starves tumors of blood supply by blocking angiogenesis. Cyclophosphamide and capecitabine are cytotoxic chemotherapy agents that damage DNA and kill rapidly dividing cancer cells. Together, they provide dual anti-tumor activity through vascular disruption and direct cytotoxicity.
Approved indications
- Metastatic breast cancer
- Colorectal cancer
- Non-small cell lung cancer
Common side effects
- Hypertension
- Proteinuria
- Neutropenia
- Anemia
- Diarrhea
- Hand-foot skin reaction
- Nausea/vomiting
- Bleeding/thrombosis
Key clinical trials
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (PHASE1, PHASE2)
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1, PHASE2)
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (PHASE1, PHASE2)
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (PHASE1, PHASE2)
- QUILT-3.088: NANT Pancreatic Cancer Vaccine (PHASE2)
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (PHASE1, PHASE2)
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (PHASE1, PHASE2)
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: